Eisai Seeks To End Aricept Deal With Pfizer Once Wyeth Acquired
This article was originally published in PharmAsia News
Executive Summary
Eisai is considering an end to its co-promotion deal with U.S.-based Pfizer for the Japanese drug maker's Aricept (donepezil) for treating Alzheimer's Disease. Eisai has not disclosed its plans, but Pfizer said in a regulatory filing it intended to fight Eisai's plan to take back the drug once Pfizer's purchase of fellow U.S. drug maker Wyeth is completed. Pfizer said Eisai has no legal basis for ending the partnership for co-promoting the $482 million-a-year drug. In the filing, Pfizer said Eisai indicated it had the right to end the contract. (Click here for more - a subscription may be required
You may also be interested in...
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.
Report Finds Digital Diabetes Tools Deliver No ‘Meaningful Clinical Benefits'
A new report from health economics group the Peterson Health Technology Institute found that apps to help patients manage their blood sugar levels delivered few of the promised benefits. However, a digital therapeutics industry association says PHTI’s research cast too narrow a net.
Merck’s Winrevair Well Positioned To Benefit From Medicare Part D Redesign
Significant cost sharing reductions under the redesign will enhance uptake of the pulmonary arterial hypertension drug. The trade-off is a 20% mandatory price discount in the catastrophic phase.